EU resolution’s medical cannabis definition too restrictive, experts say
Much of resolution 2018/2775(RSP) focuses on research, medical education and health insurance coverage, but some of the components – Article 14 in particular – have created concern around “protecting the interest of some manufacturers,” Balas noted.
A look at Article 14
Article 14 lays the foundation for what the European Parliament is calling medical cannabis:
This restrictive definition was proposed “to ensure that cannabis-based medicines which have undergone clinical trials are readily available to all EU doctors and patients, but access to medical cannabis not supported by clinical trials be decided on a national level,” United Kingdom MEP Catherine Bearder told Marijuana Business Daily.(Article 14) calls on the Commission to work with Member States to ensure that safe and controlled cannabis used for medicinal purposes can only be in the form of cannabis-derived products that have gone through clinical trials, regulatory assessment and approval.
“Legalization of cannabis for whatever reason is a national issue and isn’t a legal competency of the EU,” said Bearder, whose Liberal Democrat party supports fully legalizing cannabis and introducing a properly regulated market in the U.K.
Each country is still responsible for passing specific legislation regarding legalization, and the resolution is not binding on member states, which means each country could opt for broader definitions than those proposed by this resolution.